Karlik 1998.

Methods	Study design: parallel‐group RCT Country: not reported Number randomized: Total: 50 Per group: apraclonidine = 28, latanoprost = 22 Exclusions after randomization: not reported Number analyzed: Total: not reported Per group: not reported Unit of analysis: participants Losses to follow‐up: not reported How was missing data handled?: not reported Reported power calculation: no Unusual study design?: unclear whether the study analyzed participants or eyes
Participants	Age: not reported Females: not reported Inclusion criteria: people undergoing ALT Exclusion criteria: not reported Equivalence of baseline characteristics: no, demographic characteristics were not discussed, only medical characteristics: "Both groups had equal types of glaucoma, pigmentation, and previous surgical histories."
Interventions	Intervention 1: 1 drop apraclonidine 0.5%, 1 hour prior to surgery Intervention 2: 1 drop latanoprost 0.005%, 6 hours and 1 hour prior to surgery Length of follow‐up: Planned: not reported Actual: 6 weeks
Outcomes	Primary outcome: IOP Secondary outcomes: not reported Adverse events reported: no Intervals at which outcomes assessed: 1.5 hours; 1 day; 1, 6 weeks
Notes	Trial registration: not reported Funding sources: not reported Disclosures of interest: not reported Study period: not reported Reported subgroup analyses: no
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Sequence generation not described.
Allocation concealment (selection bias)	Unclear risk	Allocation concealment not reported.
Masking of participants and personnel (performance bias)	Unclear risk	No information on masking of participants and personnel reported.
Masking of outcome assessment (detection bias)	Unclear risk	No information on efforts to mask the outcome assessors reported.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Unclear whether there were any missing data or how they were handled.
Selective reporting (reporting bias)	Unclear risk	Unclear whether there was selective outcome reporting.
Other bias	Unclear risk	Funding sources not reported; unclear whether the participant or the eye were analyzed.